GCM
DAWN

Graham Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Graham Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,355
Closed -$469K – 1234
2025
Q4 		$469K Buy
+50,355
New +$421K 0.01% 643
2025
Q1 		– Sell
-27,950
Closed -$354K – 1342
2024
Q4 		$354K Buy
27,950
+8,862
+46% +$123K 0.01% 864
2024
Q3 		$266K Buy
+19,088
New +$272K ﹤0.01% 823

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Graham Capital Management's DAWN Position: Q1 2026 in Review

Graham Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 50,355 shares — an estimated $469K sold.

Graham Capital Management first reported a position in DAWN in Q3 2024 and held it in 3 quarters. The position peaked at $469K in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Graham Capital Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 50,355 Day One Biopharmaceuticals shares in Q1 2026, an estimated $469K.
  • Graham Capital Management first reported a position in Day One Biopharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Graham Capital Management's Day One Biopharmaceuticals position peaked at $469K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.